Trial Profile
A Part-randomised, Single Centre, Single Dose, Crossover,Phase I Study to Investigate the Impact of Changes to the Dosing Regimen on the Pharmacokinetic Profile of ODM-203 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2018
Price :
$35
*
At a glance
- Drugs AUR 109 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms KIPEV
- Sponsors Orion Pharma
- 06 Feb 2018 Status changed from recruiting to completed.
- 19 Sep 2017 Status changed from not yet recruiting to recruiting.
- 09 Aug 2017 New trial record